Biotech company Noxopharm (ASX:NOX) secured AU$1.8 million in advanced funding from Endpoints Capital against its Australian Government research and development tax incentive scheme rebate for the fiscal year 2023-2024, according to a Friday filing with the Australian Securities Exchange.
The company received the funding through a secured loan agreement over the rebate at an annual interest rate of 15.80%. The loan is repayable from R&D rebate proceeds, estimated to be around AU$2.3 million for the year ending June 30, the filing said.
Price (AUD): $0.13, Change: $+0.010, Percent Change: +8.70%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。